Genmab — December 2020
-
-
Summary points from expert feedback:
Preliminary efficacy for BCMA-directed bispecifics ranging from 60% to 80% looks very promising
Risk/benefit profiles not mature enough to identify distinguishing features but too soon to rule out Amgen’s AMG 701 based on early safety data -
KOL sees bispecifics quickly being moving up as part of combinations as far as first relapse, and eventually perhaps even into first-line treatment
Anti-BCMA CAR-T cells will have an initial first-to-market advantage but bispecifics’ ease of use should give them a leg up, especially in the community
Candidates addressing novel targets like FcRH5 and GPCR5D look highly promising for BCMA-experienced patients -
Case Report: Daratumumab in a Patient With Severe Refractory Anti-NMDA Receptor Encephalitis https://www.frontiersin.org/articles/10.3389/fneur.2020.602102/full
-
November Darzalex US salg $ 237M. (November havde 19 arbejdsdage mod 21 i oktober).
-
10 % ?
-
Så må vi se frem til den 20. februar!
-
Rigtigt gode recepttal - usd 15m mere end mine estimater. Men det er nok de færre klinikdage, der driller markedet
-
Den faldende dollar kurs betyder noget af et hak i tuden
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind